The activity of the new aminoglycoside antibiotic, amikacin, was evaluated in vitro against 219 clinical bacterial isolates. One hundred eighty-nine of the 219 strains had agar dilution minimal inhibitory concentration values of 8.0 ug/ml or less for amikacin. Comparative agar dilution studies were performed for gentamicin, kanamycin, and tobramycin. Gentamicin was the most active overall, but tobramycin and amikacin also had significant activity against most bacterial groups. The effects of divalent cations on the susceptibility ofPseudomonas aeruginosa to amikacin were evaluated, and the minimal inhibitory concentration values varied sixfold over a range of divalent cation concentrations from 0.2 to 8.75 mg%o. The effects of media and inoculum size on disk susceptibility testing with amikacin were also evaluated. In addition, a synergistic interaction between carbenicillin and amikacin against P. aeruginosa was demonstrated. Amikacin appears to be a promising new broad spectrum antimicrobial agent.
The availability of the aminoglycoside antibiotic, gentamicin, over the past several years has greatly enhanced the therapeutic approach to serious gram-negative infections. Gentamicin is active against Staphylococcus aureus, members of the family Enterobacteriaceae and, very importantly, Pseudomonas aeruginosa (17) . Disturbingly, however, reports of resistance to gentamicin among members of the family Enterobacteriaceae have begun to appear (11) . More importantly, clinical isolates of P. aeruginosa resistant to gentamicin have been reported for some time (14) , and now constitute 8% of such strains isolated in the University of Utah Hospital. Therefore, the search for new antimicrobial agents with a similar spectrum of activity has continued.
Amikacin is one of the more recently discovered agents which seems to have such activity. This antimicrobic is a semisynthetic aminoglycoside produced by acylation of kanamycin A (10) . Amikacin has been reported to have activity against a variety of gram-negative bacteria, including P. aeruginosa, and also against S. aureus. There have also been indications in previous studies that amikacin has a higher therapeutic index than other aminoglycoside agents active against P. aeruginosa (2, 18) . ' Present address: U.S. Public Health Service, Rocky Mountain Laboratory, Hamilton, Mont. 59840. In the present study, the activity of amikacin against a variety ofbacteria has been analyzed, and a regression curve has been prepared. The effects of various media on susceptibility testing with amikacin have been determined as well as the effects of divalent cations and inoculum size. In addition, studies of synergy between amikacin and carbenicillin against P. aeruginosa have been performed.
MATERIALS AND METHODS
In vitro susceptibility determinations by standard methods. Agar and broth dilution antimicrobial susceptibility determinations were carried out as outlined by Ericsson and Sherris (4) . Disk diffusion antimicrobial susceptibility determinations were performed as outlined in the Federal Register (5, 6). Stock solutions of amikacin, kanamycin (provided by Bristol Laboratories), gentamicin (Schering Corp.), and tobramycin (provided by Eli Lilly Co.) were filter sterilized, dispensed, and stored at -20 C. Serial twofold dilutions were carried out in Mueller-Hinton broth (MHB). Unless otherwise specified, the organisms to be tested were grown overnight in tryptic soy broth and adjusted to the density of 0.5 McFarland standard. The standardized inocula were diluted 1:10 and applied to the plates in the agar dilution method using the replicating device of Steers et al. (16) . The standardized inocula were applied by the cotton swab technique for the disk diffusion studies.
A total of 219 bacterial strains were analyzed. The (2, 048 ,ug/ml) in MHB was added to wells 1 through 12 of row A (top row of plate). Serial dilutions were made from wells A through G in each vertical column, leaving the bottom row (row H) with no added carbenicillin. Column no. 12 on the far right of the plate served as the MIC determination for carbenicillin, and row H at the bottom of the plate served as the MIC determination for amikacin. Antibiotic combinations ranged from 512 ,ug of carbenicillin per ml plus 32 .g of amikacin per ml down to 8 ,ug of carbenicillin per ml plus 0.015 ,ug of amikacin per ml. Each well was inoculated with 50 ,ul of the P. aeruginosa strain to be tested. The inocula were prepared as above.
RESULTS
Amikacin MIC determinations. The amikacin susceptibility of 219 bacterial strains was tested by agar dilution methodology. All strains ofthe Enterobacteriaceae tested, including those presented in Fig. 1 also quite resistant to amikacin. However, most of the P. aeruginosa strains were susceptible to concentrations of amikacin achievable in vivo. In addition, two strains of E. coli and Klebsiella that were highly resistant to gentamicin were very susceptible to amikacin in simultaneous testing.
Comparison of amikacin, kanamycin, tobramycin, and gentamicin. Agar dilution studies comparing amikacin, kanamycin, tobramycin, and gentamicin were performed for each of the 219 bacterial strains. The results comparing the percentage of strains of selected bacterial groups inhibited at various MIC values are presented in Fig. 1 through 7 . The antibiotics having the greatest in vitro activity varied with the bacterial group. For E. coli, gentamicin had the greatest activity, and amikacin was the least active of the four antibiotics (Fig. 1) . Gentamicin was also most active against Klebsiella, Enterobacter, Serratia, Acinetobacter, and Proteus-Providencia species (Fig. 2-6 ), and tobramycin was slightly more active than amikacin against these groups of organisms except for Serratia and ProteusProvidencia. In the latter cases, amikacin was more active than tobramycin (Fig. 4 and 6 ). For all these organisms, kanamycin was the least active antibiotic. In the case of P. aeruginosa, tobramycin had the greatest in vitro activity. Gentamicin was nearly as active as tobramy- cin, and amikacin was slightly less active (Fig.  7) .
Amikacin regression analysis. A scattergram of MIC versus disk zone size values was constructed for the amikacin determinations, and a line of regression was calculated using a computerized version of the formula of least squares. A linear relationship was found for the amikacin regression analysis, and the points of MIC versus zone size were fairly evenly distributed along the line (Fig. 8) .
Comparison of agar and broth dilution methods for MIC determination and evaluation of MIC versus MLC. Five strains each of E. coli, Klebsiella, Enterobacter, and P. aeruginosa (a total of 20 strains) were tested by standard agar and broth dilution methods simultaneously. The results reveal fairly close agreement for MIC values obtained by two methods with the exception of P. aeruginosa. The mean agar dilution MIC value for P. aeruginosa was 5.6 ,tg/ml, whereas the broth dilutionS value was only 0.9 ,ug/ml ( (Fig. 9) . The MIC values also demonstrated a fourfold variation over a range of Ca2+ concentrations from 0.2 to 8.75 mg%. Therefore, the concentration of divalent cations in media has a marked effect upon the amikacin MIC values for P. aeruginosa as has been observed with other aminoglycoside antibiotics. The most meaningful range would appear to be that comparable to the physiological condition in humans.
Amikacin standard curve and disk assay. An amikacin standard curve was prepared by impregnating standard blank filter paper disks with known quantities of the antibiotic. These disks were used on plates to determine the size of the zones of inhibition by the standard Bauer-Kirby method. The standard curve revealed a linear relationship between zone size and disk content over the range of 0.62 to 40 p,g of amikacin. Six commercially available amikacin disks were examined simultaneously with the standard curve disks. All six had zone sizes of 24 mm which corresponds to exactly 10 ,ug of antibiotic. 9, 1976 method was used with various agar media to determine the effects of this variable on susceptibility to amikacin, tobramycin, and gentamicin. The differences in zone size on MuellerHinton agar as compared to MHB plus agar (two sources) and tryptic soy agar were of limited significance for the three antibiotics tested against P. aeruginosa and E. coli. However, brain heart infusion agar gave significantly larger zone sizes for P. aeruginosa and significantly smaller zone sizes for E. coli. Nutrient agar gave unacceptably small zones in all cases ( Table 2 ). Effect of inoculum size on susceptibility testing with amikacin and tobramycin. Cultures of the standard E. coli strain were grown overnight in tryptic soy broth. The turbidity was adjusted to the 0.5,McFarland standard. The original culture was diluted serially and viable counts were determined by the pour plate method. Mueller-Hinton agar plates were swabbed with the standardized E. coli suspension and with the diluted inocula. Amikacin and tobramycin disks were placed on the surface, and zones of inhibition were determined after overnight incubation. The zone sizes decreased from 40 mm at 7.5 x 102 bacteria/ml to 26 mm at 7.5 x 106 bacteria/ml for amikacin.
Tobramycin showed a parallel effect with zone sizes decreasing from 44 to 29 mm.
Demonstration of synergy between amika- cin and carbenicillin against P. aeruginosa. The microtiter broth dilution method was used to assess the interaction of carbenicillin and amikacin against four strains ofP. aeruginosa. The cbmbinations ranged from a maximum of 512 ,ug of carbenicillin per ml plus 0.015 ug of amikacin per ml. An isobologram Was constructed from the MIC values obtained (Fig.  10) . The results were concave, indicating synergy. DISCUSSION Amikacin has been shown in previous studies to have activity against members ofthe Enterobacteriaceae, as well as P. aetuginosa (1, 9,-13, 18, 19) . Our studies confirm these observations, and 86% of the 219 strains tested were susceptible to 8.0 ,ug or less of amikacin per ml. Of the Enterobacteriaceae, 97% were susceptible to 8.0 ,ug or less of amikacin per ml, and the resistant strains were all members of the Proteus-Providencia group. The strains of P. aeruginosa examined were all susceptible to 32 ,tg/ml or less, and 82% were susceptible to 8 ,ug/ml or less. The studies comparing amikacin to gentamicin, tobramycin and kanamycin are also in agreement with previous findings (1, 9, 13, 18, 19) . In general amikacin is less active on a weight basis than gentamicin or tobramycin, but it is more active than kanamycin ( Fig. 1 to 7) . Although amikacin is less active than gentamicin or tobramycin in vitro, higher serum levels are achievable in man with amikacin, and its therapeutic efficacy may be equal to the other agents overall (2, 15) .
The amikacin regression analysis, relating the agar dilution MIC values to disk zone sizes for a variety of clinical isolates (Fig. 8) , demonstrates that the data points are distributed fairly evenly along the regression line except for some spreading in the high MIC range. This regression analysis can be useful for determining resistance breakpoints for amikacin. It also provides a means for estimating a range of MIC values from a given disk zone size.
Another aspect of aminoglycoside susceptibility testing that has relevance for amikacin is a comparison of broth to agar dilution method for MIC determinations. Our results indicated agreement within the limits of error of the methods for E. coli, Klebsiella, and Enterobacter. However, with Pseudomonas strains, the agar dilution values were sevenfold greater than the broth dilution values (Table 1) . This problem will likely be minimized as MHB media becomes supplemented with physiological amounts of the critical divalent cations, Ca2+ and Mg2+. This discrepancy is related to the cation content of the two media, and it has been observed with other aminoglycoside antibiotics (8) . Our studies of the effects of divalent cations on amikacin MIC values for P. aeruginosa confirm this impression since a four-to sevenfold rise in MIC values was observed over a range of Ca2+ and Mg2+ concentrations (Fig. 9) .
Differences between Mueller-Hinton agar and various other media were encountered with the disk diffusion method for both P. aerugiZ nosa and E. coli (Table 2 ). Pronounced differences were observed with-nutrient agar media. Bodey and Stewart (1) also found pronouticed media effects in amikacin susceptibility testing by the broth dilution method. Our results confirm their findings and extend them to the disk diffusion method as well.
In another study, by Yu and Washington (19) , the effect of inoculum size on amikacin susceptibility testing by the broth dilution method was evaluated. They found significant differences in MIC with variations in inoculum size. Our studies confirm and extend these findings to the disk diffusion method. Marked differences in zone size were encountered with variations in the inoculum size. These findings again emphasize the need for strict adherence to the Bauer-Kirby procedure for amnkacin susceptibility testing.
Previous studies have demonstrated a synergistic interaction between gentamicin and carbenicillin (3). The concave nature Qf the amikacin-carbenicillin isobologram (Fig. 10) suggests a synergistic interaction between these agents (3). This synergy is exemplified by an example of MIC values. At a carbenicillin concentration of 60 ,ug/ml, inhibition would have been expected in the presence of 1.6 ,g of amikacin per ml if the agents had only additive effects. However, only about 0.04 -sg/ml was required to produce growth inhibition, indicating a 40-fold increase in activity.
These studies, together with those previously reported, suggest that amikacin may prQvide a useful addition to the available antibacterial agents. It is our current clinical experience that organisms of the Enterobacteriaceae or Pseudomonas groups which are resistant to gentamicin may be, susceptible to amikacin. It has activity against the Enterobacteriaceae and staphylococci which exceeds that ofkanamycin, and it has the added advantage of activity against P. aeruginosa. It is also active in vitro against certain gentamicin-resistant Enterobacteriaceae in the present study, and it has been reported to be active against Peeudomonas and other organisms (12, 15 
